REFERENSI
RATHMELL, W. Kimryn, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. Journal of Clinical Oncology, 2022, 40.25: 2957-2995.
BEDKE, Jens, et al. The 2021 updated European association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibitor–based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. European Urology, 2021, 80.4: 393-397.
GRIMM, Marc-Oliver; LEUCHT, Katharina; FOLLER, Susan. Risk stratification and treatment algorithm of metastatic renal cell carcinoma. Journal of Clinical Medicine, 2021, 10.22: 5339.
YEKEDÜZ, Emre, et al. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Clinical genitourinary cancer, 2023, 21.1: 175-182.
ERNST, Matthew S., et al. Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma. European urology, 2023, 84.1: 109-116.
